Abstracts tagged "Kawasaki disease"

Abstract Number: 1543 • ACR Convergence 2021
Epidemiology and Disease Burden of Hospitalized Children with Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2 Infection in Canada: A Canadian Pediatric Surveillance Program National Prospective Study
Tala El Tal¹, Marie-Paule Morin², Shaun Morris³, Roberta Berard⁴, Daniel Farrar⁵, Fatima Kakkar⁶, Charlotte Moore-Hepburn⁷, Elie Haddad², Rosie Scuccimarri⁸ and Rae Yeung⁹, ¹University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, ²CHU Sainte-Justine, Montréal, QC, Canada, ³Centre for Global Child Health, The Hospital for Sick Children, Division of Infectious Diseases, The Hospital for Sick Children, Toronto; Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, Toronto, ON, Canada, ⁴London Health Sciences Centre, London, ON, Canada, ⁵Centre for Global Child Health, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Division of Infectious Diseases, CHU Sainte-Justine, Montréal, QC, Canada, ⁷Division of Paediatric Medicine, Hospital for Sick Children, Toronto, ON, Canada, ⁸McGill University/Montreal Children's Hospital, Montréal, QC, Canada, ⁹The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: As of May 2021, Canada had reached over 1.3 million confirmed cases of SARS-CoV-2 infection, and over 25,000 deaths. This study identified children in…
Abstract Number: 043 • 2020 Pediatric Rheumatology Symposium
Resolution of Coronary Artery Changes in Patients with Refractory Kawasaki Disease with Prolonged Course of Infliximab: A Case Series
Shelley Shi¹ and Anusha Ramanathan ¹, ¹Kaiser Permanente Los Angeles, Los Angeles, California
Background/Purpose: Treatment for patients with Kawasaki Disease (KD) refractory to standard therapy is controversial. Most experts recommend a second dose of IVIG [1], and for…
Abstract Number: 058 • 2020 Pediatric Rheumatology Symposium
Kawasaki Disease in Ontario Children from 1995-2017: A Population-based Descriptive Analysis
Cal Robinson ¹, Rahul Chanchlani ¹, Megan Schlorff ¹, Francis Lao ¹, Tapas Mondal ¹, Catherine Demers ¹, Elizabeth Darling ¹, Sandeep Brar ², Rulan Parekh ³, Hsien Seow ¹, Eric Benchimol ⁴ and Michelle Batthish¹, ¹McMaster University, Hamilton, Canada, ²University of California, San Fransisco, ³University of Toronto, Toronto, Canada, ⁴University of Ottawa, Ottawa, Canada
Background/Purpose: Kawasaki disease (KD) is a childhood vasculitis with rising global incidence and the most common cause of childhood acquired heart disease in the developed…
Abstract Number: 084 • 2020 Pediatric Rheumatology Symposium
Kawasaki Disease Shock Syndrome: A Single Center Cohort
Monica Bray¹, Jennifer Rammel ², Andrea Ramirez ³, Kristen Sexson ⁴, Fong Lam ⁵, Eyal Muscal ¹ and Marietta De Guzman ³, ¹Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, ²Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁴Section of Cardiology, Department of Pediatrics, Baylor College of Medicine, Houston, ⁵Section of Critical Care, Department of Pediatrics, Baylor College of Medicine, Houston
Background/Purpose: Kawasaki disease (KD) is a well described vasculitis of childhood that is the leading cause of acquired heart disease in developed countries. Kawasaki disease…
Abstract Number: 103 • 2020 Pediatric Rheumatology Symposium
Unexpectedly High Incidence of Kawasaki Disease in a Well-Characterized Population in Atlantic Canada
Abdulrahman Alkanhal¹, Joseph , Saunders ², Fajer Altammar ³, Adam Huber ⁴, Andrew Lynk ², Alison MacLeod ⁵, Oliva Ortiz-Alvarez ⁶, Meighan Adams ², Suzanne Ramsey ⁷, Elizabeth Stringer ⁷, Andrew Warren ² and Bianca Lang ⁸, ¹University of Alberta, Edmonton, Alberta, Canada, ²Dalhousie University, Halifax, Canada, ³Mcmaster University, Hamilton, Canada, ⁴IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ⁵Annapolis Valley Health, Kentville, Canada, ⁶St Martha's Regional Hospital, Antigonish, Canada, ⁷IWK Health Centre, Halifax, Canada, ⁸Dalhousie University - Halifax, Halifax, Canada
Background/Purpose: Kawasaki Disease (KD), a systemic vasculitis of unknown etiology, is now the leading cause of acquired heart disease in children in North America. Its…
Abstract Number: 126 • 2020 Pediatric Rheumatology Symposium
Cyclophosphamide as Rescue Therapy for Kawasaki Disease with Peripheral Vascular Disease: A Single Center Experience
Ugo Awa¹, Monica Bray ² and Marietta De Guzman ³, ¹Baylor College of Medicine, Houston, ²Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
Background/Purpose: Kawasaki Disease (KD) is the most common systemic vasculitis affecting children 5 years and younger. With coronary vessel involvement, KD is now the most…
Abstract Number: 141 • 2020 Pediatric Rheumatology Symposium
Cyclophosphamide Use in Treatment of Refractory Kawasaki Disease: A Single Center Case Series of 10 Patients and Literature Review
Olha Halyabar¹, Mary Beth Son ², Margaret Chang ³ and Robert Sundel ¹, ¹Children's Hospital/Boston Medical Center, Boston, ²Boston Children's Hospital, Boston, Massachusetts, ³Boston Children's Hospital, Boston
Background/Purpose: Intravenous immunoglobulin (IVIG) effectively treats vasculitis of the coronary arteries in the large majority of Kawasaki Disease (KD) patients. However, approximately 25% of patients…
Abstract Number: 1737 • 2019 ACR/ARP Annual Meeting
Systemic Vascular Involvement in Kawasaki Disease: A Single Center Cohort
Monica Bray¹, Andrea Ramirez ¹, Eyal Muscal ¹ and Marietta De Guzman ², ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: Kawasaki disease is classically thought to be a monophasic disease that primarily targets the coronary arteries. The American Heart Association Kawasaki guidelines note that…
Abstract Number: 1739 • 2019 ACR/ARP Annual Meeting
Kawasaki Disease Shock Syndrome – More Common Than We Think: Our Experience at Chandigarh, North India
RAKESH KUMAR¹, Himanshi Chaudhary ¹, Manphool Singhal ² and Surjit Singh ¹, ¹Allergy Immunology Unit, Department pf Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Department of Radiodiagnosis and Imaging, PGIMER, Chandigarh, India
Background/Purpose: Approximately 5% patients with Kawasaki disease (KD) can present with cardiovascular collapse-the KD Shock Syndrome (KDSS). This is an unusual presentation of KD and…
Abstract Number: 1743 • 2019 ACR/ARP Annual Meeting
Kawasaki Disease: Is Intravenous Immunoglobulin Alone Adequate for the Child with Kawasaki Disease and Coronary Artery Lesions? A Retrospective Study of 65 Children with Kawasaki Disease from a Single North Indian Centre
Manjari Agarwal ¹, Sumidha Mittal ¹, Anju Singh ¹, Neeraj Agarwal ² and Sujata Sawhney¹, ¹Department of pediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India, New Delhi, India, ²Sir Gangaram Hospital, New delhi, India
Background/Purpose: Steroid use in Kawasaki disease (KD)is controversial and has swung from contraindicated, to maybe & now perhaps “should be given to all.”(1) Currently, standard…
Abstract Number: 922 • 2018 ACR/ARHP Annual Meeting
Anakinra Treatment Prevents Myocardial Mechanical Dysfunction and Inhibits Histologic Evidence of Myocardial Inflammation in the Mouse Model of Kawasaki Disease
Mark Gorelik^1,2, Youngho Lee³, Masanori Abe⁴, Thomas Andrews⁵, Jean Patterson¹, Magali Noval Rivas⁴, Gregory Aune⁵ and Moshe Arditi⁴, ¹Immunology and Virology, Texas Biomedical Research Institute, San Antonio, TX, ²Pediatrics, Baylor College of Medicine, Houston, TX, ³Department of Cell Biology, Hospital for Sick Children, Toronto, ON, Canada, ⁴Pediatrics, Cedars Sinai, Beverly Hills, CA, ⁵Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: Kawasaki disease (KD) is an acute, febrile illness of childhood with sequelae of coronary artery aneurysms and cardiac fibrosis, and is the most common…
Abstract Number: 2028 • 2018 ACR/ARHP Annual Meeting
Microwave and Magnetic (M2) Myocardial Proteomics in the Mouse Model of Kawasaki Disease Demonstrates Normalization of the Proteome after Interleukin-1 Inhibition, Potential Novel Biomarkers, and Suggests New Insights into Mechanism of Disease
Mark Gorelik¹, Carol Chase², Magali Noval Rivas³, Jean Patterson¹, Moshe Arditi³ and Thomas Forsthuber², ¹Immunology and Virology, Texas Biomedical Research Institute, San Antonio, TX, ²University of Texas San Antonio, San Antonio, TX, ³Pediatrics, Cedars Sinai, Beverly Hills, CA
Background/Purpose: Kawasaki disease (KD), a predominantly coronary vasculitis of childhood, remains the most common cause of acquired heart disease of childhood in the developed world,…
Abstract Number: 2937 • 2017 ACR/ARHP Annual Meeting
Genetic Variants in HLA-C and Class I Pathway Genes Influence Susceptibility to Kawasaki Disease
Chisato Shimizu¹, Jihoon Kim², Hariklia Eleftherohorinou³, Victoria Wright³, Long Hoang⁴, Adriana Tremoulet⁵, Alessandra Franco⁶, Martin Hibberd⁴, Atsushi Takahashi^7,8, Michiaki Kubo⁹, Kaoru Ito¹⁰, Toshihiro Tanaka^10,11, Yoshihiro Onouchi^10,12, Lachlan Coin³, Michael Levin³, Jane Burns¹³ and Hiroko Shike¹⁴, ¹Pediatrics, University of California San Diego, School of Medicine, La Jolla, CA, ²Medicine, University California San Diego, School of Medicine, Division of Biomedical Informatics, La Jolla, CA, ³Imperial College London, London, United Kingdom, ⁴Genome Institute of Singapore, Singapore, Singapore, ⁵Pediatrics, University California San Diego, School of Medicine, La Jolla, CA, ⁶Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, ⁷Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, ⁸Department of Genomic Medicine, National Cerebral And Cardiovascular Center, Suita, Japan, ⁹RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, ¹⁰Laboratory for Cardiovascular Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, ¹¹Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo, Japan, ¹²Department of Public Health, Chiba University Graduate School of Medicine, Chiba, Japan, ¹³Pediatrics, University California San DIego, School of Medicine, San Diego, CA, ¹⁴Penn State Hershey Medical Center, Hershey, PA
Background/Purpose: Host genetics influence susceptibility to Kawasaki disease (KD), an acute pediatric vasculitis, and genome wide association studies (GWAS) have detected variants with modest effects…
Abstract Number: 32 • 2017 Pediatric Rheumatology Symposium
High Mobility Group Box 1 Protein in Children with Kawasaki Disease and Systemic Juvenile Idiopathic Arthritis
Hon Yan Ng¹, Stefan Slomp², Tracy Wilson-Gerwing³, Joan Dietz⁴, Abid Lodhi⁵, Tanya Holt⁶ and Alan Rosenberg³, ¹Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²Pediatrics, Emergency Medicine, University of Alberta, Edmonton, AB, Canada, ³Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵Regina Qu'appelle Health Region, Regina, SK, Canada, ⁶University of Saskatchewan, Sasktoon, SK, Canada
Background/Purpose: High Mobility Group Box 1 Protein (HMGB1) is a nuclear protein that stabilizes DNA and modulates gene expression. In sepsis and in certain other…
Abstract Number: 102 • 2017 Pediatric Rheumatology Symposium
Duration of High-Dose Aspirin Therapy Does Not Affect Coronary Artery Outcomes in Kawasaki Disease
Karl Migally¹, Elizabeth A. Braunlin¹, Lei Zhang² and Bryce A. Binstadt³, ¹Pediatric Cardiology, University of Minnesota, Minneapolis, MN, ²Clinical and Translational Sciences Institute, University of Minnesota, Minneapolis, MN, ³Pediatric Rheumatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Kawasaki Disease (KD) is an acute vasculitis targeting the coronary arteries. Prompt treatment with intravenous immunoglobulin (IVIg) reduces the occurrence and potentially the progression…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].